May 8 (Bloomberg) -- Johnson & Johnson gave the rights to an experimental AIDS drug to a charity that’s testing the medicine in a vaginal ring to prevent HIV infection.
J&J gave the global rights to develop and market dapivirine to the International Partnership for Microbicides, a Silver Spring, Maryland-based organization that works on developing HIV prevention tools for women, IPM said today in a statement.
The agreement expands a previous partnership in which IPM held the drug rights for developing nations. The group is testing dapivirine in a vaginal ring in two late-stage studies in Africa and may in the future combine the drug with contraceptives.
“Women are in a race against time for new HIV prevention methods and they need innovative tools to protect themselves,” Zeda Rosenberg, IPM’s chief executive officer, said in the statement.
To contact the reporter on this story: Simeon Bennett in Geneva at firstname.lastname@example.org
To contact the editors responsible for this story: Phil Serafino at email@example.com Bruce Rule, Andrew Pollack